KAJAL PATEL: Open Payments
NPI 1841987849 · HILLSBOROUGH, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$491 in 22 payments from 9 companies in 2025. Trend: 2023 $86 · 2024 $394 · 2025 $491
Food & beverage: $491
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $143 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $93 |
| Novo Nordisk Inc | 5 | $84 |
| AstraZeneca Pharmaceuticals LP | 3 | $53 |
| ABBVIE INC. | 2 | $35 |
| Lundbeck LLC | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
Products named: REXULTI, Kerendia, Ozempic, FARXIGA, VRAYLAR, CAPLYTA, Rybelsus, Auvelity.
Industry payments across NJ — which companies pay providers there.
